A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Male and female, ages 18 to 70 years
Body weight >40 kg, body mass index (BMI) of 18 to 40 kg/m2
Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.
Diagnosed with non-plaque psoriasis
Previously received tyrosine kinase 2 (TYK2) inhibitors
Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects
Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
Parallel
Tyk2 inhibitor
DrugSpecific dose of Tyk2 inhibitor on specific days
Placebo
DrugSpecified dose of Placebo on specified days.
The Percentage of Participants Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Week 12
Percentage of Participants With PASI-90, PASI-100 on Week 12
Percentage of Participants on Week 12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
Change From Baseline in DLQI Scores to Week 12
Change From Baseline in BSA to Week 12
Click on the lead sponsor to view all of their trials.
